Apimeds Pharmaceuticals US, Inc. 10-Q filing
Filed 2025-08-19 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0001213900-25-078507
- Form type
- 10-Q
- CIK
- 0001894525
- Primary document
- https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Apimeds Pharmaceuticals US, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-3.0M | - | - |
| Net Income | $-3.1M | - | - |
| Eps Basic | -0.33 | - | - |
| Eps Diluted | -0.33 | - | - |
| Cash And Equivalents | $8.7M | - | - |
| Total Assets | $10.5M | - | - |
| Total Liabilities | $809,002 | - | - |
| Shareholders Equity | $9.7M | - | - |
| Operating Cash Flow | $-3.4M | - | - |
| Capital Expenditures | $13,369 | - | - |